Mayne Pharma treatment for chronic breathlessness approved by TGA

20 February 2019 | Mayne Pharma Group Limited (ASX: MYX) is pleased to announce that the Therapeutic Goods Administration (TGA) has approved KAPANOL® low dose sustained-release 10mg and 20mg morphine capsules for the treatment of chronic breathlessness in…

Read More

Nominations open for the Bionics Institute Award for Excellence in Medical Device Innovation

15 February 2019 | Nominations are now open for the Bionics Institute Award for Excellence in Medical Device Innovation. The 2019 Bionics Institute Award acknowledges an individual who, through their innovation, has made a significant impact on the…

Read More

Cartherics and panCELLa announce collaborative agreement to develop pluripotent cell lines for cell therapy

13 February 2019  Cartherics and panCELLa are pleased to announce their collaboration to research, develop and commercialise products for the treatment of cancer and other debilitating diseases using cell therapy. panCELLa will integrate their exclusive FailSafeTM technology into Cartherics’ proprietary…

Read More

Nucleus Network expands early phase trial capacity in Australia with acquisition of Q-Pharm

11 February 2019 Nucleus Network recently announced its acquisition of Q-Pharm, a 62-bed dedicated early-phase clinical trial facility based in the Herston health precinct in Brisbane. Q-Pharm was previously wholly owned by the QIMR Berghofer Medical Research Institute.…

Read More


News & opinion

Member Directory